Efficacy measures in patients aged <70 and ≥70 years
| . | <70 y (n = 95) . | ≥70 y (n = 50) . | Total (N = 145) . |
|---|---|---|---|
| BOR, n (%) | |||
| CR | 21 (22.1) | 15 (30.0) | 36 (24.8) |
| PR | 25 (26.3) | 9 (18.0) | 34 (23.4) |
| Stable disease | 16 (16.8) | 6 (12.0) | 22 (15.2) |
| PD | 18 (18.9) | 12 (24.0) | 30 (20.7) |
| Not evaluable | 15 (15.8) | 8 (16.0) | 23 (15.9) |
| ORR (CR + PR) | 46 (48.4) | 24 (48.0) | 70 (48.3) |
| 95% CI for ORR | 38.0-58.9 | 33.7-62.6 | 39.9-56.7 |
| 95% CI for CR | 14.2-31.8 | 17.9-44.6 | 18.0-32.7 |
| . | <70 y (n = 95) . | ≥70 y (n = 50) . | Total (N = 145) . |
|---|---|---|---|
| BOR, n (%) | |||
| CR | 21 (22.1) | 15 (30.0) | 36 (24.8) |
| PR | 25 (26.3) | 9 (18.0) | 34 (23.4) |
| Stable disease | 16 (16.8) | 6 (12.0) | 22 (15.2) |
| PD | 18 (18.9) | 12 (24.0) | 30 (20.7) |
| Not evaluable | 15 (15.8) | 8 (16.0) | 23 (15.9) |
| ORR (CR + PR) | 46 (48.4) | 24 (48.0) | 70 (48.3) |
| 95% CI for ORR | 38.0-58.9 | 33.7-62.6 | 39.9-56.7 |
| 95% CI for CR | 14.2-31.8 | 17.9-44.6 | 18.0-32.7 |
| . | <70 y (n = 46) . | ≥70 y (n = 24) . | Total (N = 70) . |
|---|---|---|---|
| Time to CR/PR, d, median (min, max) | 41.5 (35, 247) | 41.0 (36, 142) | 41.0 (35, 247) |
| . | <70 y (n = 46) . | ≥70 y (n = 24) . | Total (N = 70) . |
|---|---|---|---|
| Time to CR/PR, d, median (min, max) | 41.5 (35, 247) | 41.0 (36, 142) | 41.0 (35, 247) |
| . | <70 y (n = 21) . | ≥70 y (n = 15) . | Total (N = 36) . |
|---|---|---|---|
| Time to CR, d, median (min, max) | 42.0 (37, 247) | 41.0 (36, 59) | 42 (36, 247) |
| . | <70 y (n = 21) . | ≥70 y (n = 15) . | Total (N = 36) . |
|---|---|---|---|
| Time to CR, d, median (min, max) | 42.0 (37, 247) | 41.0 (36, 59) | 42 (36, 247) |
| . | <70 y (n = 49) . | ≥70 y (n = 24) . | Total (N = 73) . |
|---|---|---|---|
| Median PFS, mo (95% CI) | 3.81 (2.69-8.08) | 7.36 (2.99-NA) | 4.93 (2.89-8.31) |
| . | <70 y (n = 49) . | ≥70 y (n = 24) . | Total (N = 73) . |
|---|---|---|---|
| Median PFS, mo (95% CI) | 3.81 (2.69-8.08) | 7.36 (2.99-NA) | 4.93 (2.89-8.31) |
| . | <70 y (n = 17) . | ≥70 y (n = 6) . | Total (N = 23) . |
|---|---|---|---|
| Median DOR, mo (95% CI) | 9.26 (4.63-NA) | NR | 13.37 (6.87-NA) |
| . | <70 y (n = 17) . | ≥70 y (n = 6) . | Total (N = 23) . |
|---|---|---|---|
| Median DOR, mo (95% CI) | 9.26 (4.63-NA) | NR | 13.37 (6.87-NA) |
| . | <70 y (n = 63) . | ≥70 y (n = 33) . | Total (N = 96) . |
|---|---|---|---|
| Median OS, mo (95% CI) | 9.89 (6.14-12.09) | 8.90 (6.74-12.42) | 9.53 (6.93-11.47) |
| . | <70 y (n = 63) . | ≥70 y (n = 33) . | Total (N = 96) . |
|---|---|---|---|
| Median OS, mo (95% CI) | 9.89 (6.14-12.09) | 8.90 (6.74-12.42) | 9.53 (6.93-11.47) |
BOR, best overall response; CR, complete response; DOR, duration of response; max, maximum; min, minimum; NA, not available; NR, not reached; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response.